Key Findings
Hovione, a leading pharmaceutical services company, has commissioned the world’s first next-generation ConsiGma® CDC Flex continuous tableting system at its facility in New Jersey, USA. This groundbreaking implementation establishes a fully integrated continuous flow manufacturing pathway from spray-dried amorphous solid dispersions (ASDs) directly to tablet production at its U.S. site. This investment marks a significant advancement in pharmaceutical manufacturing, promising substantial improvements in efficiency, flexibility, and quality control, thereby accelerating the timeline from drug development to commercial production.
Technical and Clinical Details
- ConsiGma® CDC Flex Capabilities: The ConsiGma® CDC Flex is a component of GEA Pharma Systems’ continuous manufacturing platform, specifically optimized for producing amorphous solid dispersions (ASDs) to enhance the solubility of poorly soluble drugs. The system integrates a sequence of processes from raw material feeding, blending, granulation, drying, tableting, to coating, all performed continuously.
- Continuous Flow Manufacturing: Unlike traditional batch manufacturing, continuous flow manufacturing processes operate without interruption, drastically reducing production cycle times and increasing manufacturing flexibility. This allows for rapid responses to fluctuations in market demand.
- Enhanced Quality Control: Continuous processes enable real-time quality monitoring and control. By integrating Process Analytical Technology (PAT) tools, continuous verification of product quality is achieved, minimizing batch-to-batch variability and enhancing overall product consistency and reliability.
- Integrated Pathway from ASDs: ASDs are crucial for improving the bioavailability of poorly soluble drugs. This system provides a seamless, continuous flow from ASD manufacturing to final tablet formation, ensuring high-efficiency and high-quality product supply.
Background and Context
The pharmaceutical industry is progressively shifting towards continuous manufacturing from traditional batch processing to improve efficiency, reduce costs, and enhance product quality. Regulatory bodies like the FDA actively encourage the adoption of more efficient and robust manufacturing processes, making continuous manufacturing a standard for future drug production. Hovione’s adoption of the ConsiGma® CDC Flex positions it at the forefront of this trend as a Contract Development and Manufacturing Organization (CDMO), offering a significant competitive advantage to its clients, particularly for complex formulations and poorly soluble drugs.Strategic Significance and Outlook
Hovione’s operationalization of the ConsiGma® CDC Flex symbolizes the cutting-edge evolution of pharmaceutical manufacturing capabilities in the U.S. This system is set to shorten the development timelines for new drugs and accelerate their time-to-market, ensuring that patients receive necessary treatments more quickly. Through this investment, Hovione will meet the growing demand from pharmaceutical companies seeking advanced manufacturing technologies, reinforcing its leadership in the CDMO market. Looking ahead, continuous manufacturing technology is expected to become more widespread, forming the foundation for enhanced efficiency and innovation across the entire pharmaceutical manufacturing industry.
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
